Results 51 to 60 of about 3,260 (145)

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma

, 2022
Outcomes for marginal zone lymphoma (MZL) and follicular lymphoma (FL) remain suboptimal, owing to the limited number of approved agents and the incurable nature of the diseases.
Chan, H, Tam, CS, Tan, Z, Phillips, T, Eom, HS, Trotman, J, Oh, SY, Allewelt, H, Stern, JC, Tedeschi, A, Huang, J, Opat, S, Novotny, W, Johnston, P   +13 more
core   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia

, 2023
This article examined the cost-effectiveness of zanubrutinib and ibrutinib for managing relapsed and refractory chronic lymphocytic leukemia from the viewpoint of payers in China and the US. Markov models were employed to conduct comparisons.
Jingyao Xu (16800611), Xiuhua Zhang (486216), Chuang Chen (496438), Jianhui Yang (536606), Tao Zhou (117050), Yizhang Chen (4166200), Ziye Zhou (11701808), Rongqi Li (11795351), Zhongjiang Ye (17474996), Chenxiang Wang (748705), Jing Fu (177892)   +10 more
core   +1 more source

No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects

Clinical and Translational Science, 2020
This thorough QT (TQT) study evaluated the effect of zanubrutinib on electrocardiogram (ECG) parameters by using concentration‐QTc (C‐QTc) analysis as the primary analysis for this study.
Song Mu, Borje Darpo, Zhiyu Tang, William Novotny, Manal Tawashi, Hongqi Xue, Michael Willett, Leo Lin, Sri Sahasranaman, Ying C. Ou   +9 more
doaj   +1 more source

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

European Journal of Haematology, EarlyView.
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao, Dieu Nguyen, Victoria White, Patricia M. Livingston, Chan Y. Cheah   +4 more
wiley   +1 more source

Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)

Therapeutic Advances in Medical Oncology
Background: There are no head-to-head studies comparing the efficacy of the Bruton tyrosine kinase inhibitors, zanubrutinib and acalabrutinib, in relapsed or refractory chronic lymphocytic leukemia (R/R CLL).
Mazyar Shadman, Jennifer R. Brown, Rhys Williams, Leyla Mohseninejad, Keri Yang, Pal Rakonczai, Nicole Lamanna, Sheng Xu, Aileen Cleary Cohen, Susan M. O’Brien, Alessandra Tedeschi, Constantine S. Tam   +11 more
doaj   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Zanubrutinib: First Approval

, 2020
Compliance with Ethical StandardsFunding The preparation of this review was not supported by any external funding.Conflict of interest  During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the
Yahiya Y. Syed (6594444)
core   +1 more source

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp, Maikel Borg, Jens H. J. Bos, Catharina C. M. Schuiling‐Veninga, Katja Taxis, Frank G. A. Jansman   +5 more
wiley   +1 more source